Bayer is preparing to start a phase 3 trial of its cell therapy candidate bemdaneprocel for Parkinson's disease after discussing phase 1 results with the FDA, while its experimental gene therapy is ...

Foreign reference pricing frameworks often differ from the way the US has historically valued medical innovation. A more ...

Growing support for perioperative vs neoadjuvant therapy, but many questions yet to be ans ...

The FDA has cleared several oncology products over the past few days, ranging from therapies to diagnostic and imaging tools.

Bayer has struck a deal to buy Perfuse Therapeutics for $300 million upfront. The buyout, which includes up to $2.15 billion in milestones, will give Bayer control of an eye disease implant that ...

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease ...

Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA ® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD) by 24 weeks, ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

These companies aren’t just innovating—they’re building factories, facilities, and systems that strengthen U.S. supply chains and create domestic jobs.

Kidney disease affects about 37 million American adults and occurs when the kidneys become damaged and can’t filter waste, excess water, and toxins from the blood. Diabetes and high blood pressure are ...

Perfuse reported phase 2 data on PER-001 in glaucoma and diabetic retinopathy last year. (RedVector/GettyImages) Bayer has struck a deal to buy Perfuse Therapeutics for $300 million upfront. The ...